NASH is a progressive form of NAFLD, one of the most common chronic liver diseases worldwide.1,2 It is a chronic inflammatory condition accompanied by hepatocyte damage and varying degrees of fibrosis, which may progress to cirrhosis.3,4 Pathogenic mechanisms of NASH are complex and may involve insulin resistance, accumulation of lipids, lipotoxicity, oxidative stress and injury, and gut microbiota disruption.5–7. The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.